Sanofi: insider trades.
Sanofi reported 4 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 1 open-market purchase ($5.1M) and 0 sales, across 2 companies.
- Transactions
- 4
- Purchases (P)
- 1
- Sales (S)
- 0
- Companies
- 2
- Name as filed
- Sanofi
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | TenPercentOwner | 2 |
| Attovia Therapeutics, Inc. (ATTO) | TenPercentOwner | 2 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-10 | Latigo Biotherapeutics, Inc. | C | 494,800 | — | 494,800 | Form 4 |
| 2026-08-10 | Latigo Biotherapeutics, Inc. | C | 177,978 | — | 672,788 | Form 4 |
| 2026-08-06 | Attovia Therapeutics, Inc. | C | 782,855 | — | 782,855 | Form 4 |
| 2026-08-06 | Attovia Therapeutics, Inc. | P | 300,000 | $17 | 1,082,855 | Form 4 |
Questions
What stock did Sanofi buy or sell?
Sanofi reported 4 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 1 open-market purchase ($5.1M) and 0 sales, across 2 companies.
Is Sanofi the same person as other filers with this name?
This page covers SEC CIK 1121404 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/sanofi-1121404.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.